13634 Tildrakizumab provides early predictability of...

Journal of the American Academy of Dermatology 2020 / 12 Vol. 83; Iss. 6

13634 Tildrakizumab provides early predictability of response in patients with moderate to severe psoriasis: Results from reSURFACE 1 and reSURFACE 2 phase 3 trials

Warren, Richard B., Iversen, Lars, Puig, Luis, Fumero, Emilio, López, Andreu Schoenenberger, Feldman, Steven R.
How much do you like this book?
What’s the quality of the file?
Download the book for quality assessment
What’s the quality of the downloaded files?
Volume:
83
Journal:
Journal of the American Academy of Dermatology
DOI:
10.1016/j.jaad.2020.06.127
Date:
December, 2020
File:
PDF, 133 KB
2020
Conversion to is in progress
Conversion to is failed